Compositions of TLR7 and/or TLR8 agonists conjugated to lipids
A conjugated compound of formula Q-Z—R 4 wherein Q is a TLR7 and/or TLR8 agonist and Z—R 4 is a lipid covalently linked to an amino acid or peptide coupled to a polyamine group, and a process for the manufacture of the conjugated compound, as well as a complex formed between the conjugated compound and a polyanionic molecule and a pharmaceutical composition containing the conjugated compound or complex. Also described is the use of the conjugated compound or complex in the treatment of infection, cancer or immune disorders or for use in vaccines.
1. A conjugated compound containing a purine derivative agonist of TRL7 and/or TRL8, said conjugated compound being chosen among compounds of formula (I′):
a tautomer thereof or a pharmaceutically acceptable salt of said compound or tautomer, wherein:
R 2 is C 1 -C 10 alkylamino;
X is a phenylene;
Y is NH or —C(O)—; and
Z—R 4 is selected from the group consisting of:
wherein:
R 6 is the specific side chain of an amino acid selected from the group consisting of L or D isomers of alanine, valine, leucine, isoleucine, phenylalanine, tryptophan, methionine, glycine, serine, threonine, cysteine, tyrosine, asparagine, glutamine, aspartic acid, glutamic acid, lysine, arginine, proline and histidine;
l is 0 or 1;
p is integer from 0 to 6;
m, n, o, and q, identical or different, are integers from 1 to 4; and
R 4 is a lipid of formula VII or VIII:
wherein:
R 7 and R 8 independently of each other are a linear or branched hydrocarbon chain comprising from 10 to 24 carbon atoms, and which optionally contains from 2 to 4 double or triple bonds,
G 1 is a single bond, —NH— or —O—,
G 2 is a single bond or (—CH 2 —)r, and
r is an integer from 1 to 6.
2. The conjugated compound according to claim 1 , wherein —Z— is selected from the group consisting of:
3. The conjugated compound according to claim 1 , wherein R 4 is of formula (VII):
wherein:
r is an integer from 1 to 4,
G 1 is a single bond,
R 7 and R 8 , identical or different, are selected from the group consisting of tetradecyl, hexadecyl, octadecyl, oleyl, phytanyl, C18:2 alkenyl, C18:3alkenyl and C18:1 alkenyl.
4. The conjugated compound according to claim 1 , wherein R 4 is of formula (VIII):
wherein G 2 is a single bond or (—CH 2 —)r, wherein r is an integer from 1 to 6.
5. The conjugated compound according to claim 1 , wherein said conjugated compound is selected from the group consisting of:
bis(3,7,11,15-tetramethylhexadecyl) 1-(4-((6-amino-2-(butylamino)-8-hydroxy-9H-purin-9-yl)methyl)phenyl)-1-oxo-2,6,11,15-tetraazaoctadecan-18-ylphosphonate,
bis(3,7,11,15-tetramethylhexadecyl) 1-(4-((6-amino-2-(butylamino)-8-hydroxy-9H-purin-9-yl)methyl)phenyl)-1,4-dioxo-2,5,9,14,18-pentaazahenicosan-21-ylphosphonate,
di(Z)-octadec-9-enyl 1-(4-((6-amino-2-(butylamino)-8-hydroxy-9H-purin-9-yl)methyl)phenyl)-1-oxo-2,6,11,15-tetraazaoctadecan-18-ylphosphonate,
di(Z)-octadec-9-enyl 1-(4-((6-amino-2-(butylamino)-8-hydroxy-9H-purin-9-yl)methyl)phenyl)-1,4-dioxo-2,5,9,14,18-pentaazahenicosan-21-ylphosphonate,
dihexadecyl 1-(4-((6-amino-2-(butylamino)-8-hydroxy-9H-purin-9-yl)methyl)phenyl)-1-oxo-2,6,11,15-tetraazaoctadecan-18-ylphosphonate,
dihexadecyl 1-(4-((6-amino-2-(butylamino)-8-hydroxy-9H-purin-9-yl)methyl)phenyl)-1,4-dioxo-2,5,9,14,18-pentaazahenicosan-21-ylphosphonate,
(S)-dihexadecyl 19-amino-5-(4-(2-(4-((6-amino-2-(butylamino)-8-hydroxy-9H-purin-9-yl)methyl)benzamido)acetamido)butyl)-6-oxo-4,7,11,16-tetraazanonadecylphosphonate,
(S)-bis(3,7,11,15-tetramethylhexadecyl)-19-amino-5-(4-(2-(4-((6-amino-2-(butylamino)-8-hydroxy-9H-purin9-yl)methyl)benzamido)acetamido)butyl)-6-oxo-4,7,11,16-tetraazanonadecylphosphonate,
(S)-Dihexadecyl-1-amino-15-(2-(4-((6-amino-2-(butylamino)-8-hydroxy-9H-purin-9-yl)methyl)benzamido)acetamido)-14-oxo-4,9,13,20-tetraazatricosan-23-ylphosphonate,
(S)-bis(3,7,11,15-tetramethylhexadecyl)-1-amino-15-(2-(4-((6-amino-2-(butylamino)-8-hydroxy-9H-purin-9-yl)methyl)benzamido)acetamido)-14-oxo-4,9,13,20-tetraazatricosan-23-ylphosphonate,
(S)-Dihexadecyl-1-amino-15-(4-((6-amino-2-(butylamino)-8-hydroxy-9H-purin-9-yl)methyl)benzamido)-14-oxo-4,9,13,20-tetraazatricosan-23-ylphosphonate,
(S)-bis(3,7,11,15-tetramethylhexadecyl)-1-amino-15-(4-((6-amino-2-(butylamino)-8-hydroxy-9H-purin-9-yl)methyl)benzamido)-14-oxo-4,9,13,20-tetraazatricosan-23-ylphosphonate,
(S)-dihexadecyl-21-amino-5-(4-((6-amino-2-(butylamino)-8-hydroxy-9H-purin-9-yl)methyl)phenylcarbamoyl)-8-oxo-4,9,13,18-tetraazahenicosylphosphonate,
bis(3,7,11,15-tetramethylhexadecyl)-(S)-21-amino-5-(4-((6-amino-2-(butylamino)-8-hydroxy-9H-purin-9-yl)methyl)phenylcarbamoyl)-8-oxo-4,9,13,18-tetraazahenicosylphosphonate, and
(3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10, 11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl 3-(4-(3-(4-((6-amino-2-(butylamino)-8-hydroxy-9H-purin-9yl)methyl)benzamido)propylamino)butylamino)propylcarbamate,
a tautomer thereof or a pharmaceutically acceptable salt of said compound or tautomer.
6. A pharmaceutical composition comprising the conjugated compound according to claim 1 and a pharmaceutically acceptable excipient or carrier.
7. A vaccine comprising the conjugated compound according to claim 1 .